Core Viewpoint - Bio-Path Holdings, Inc. reports significant progress in its clinical trials for BP1001-A in solid tumors and prexigebersen in Acute Myeloid Leukemia (AML), indicating potential for effective treatment options in challenging patient populations [1][2][3]. Group 1: Clinical Trial Updates - The first solid tumor patient treated with a higher dose of BP1001-A (90 mg/m) has shown tumor regression and stable disease after ten treatment cycles, marking a significant milestone for the company [2][5]. - The Phase 1/1b trial of BP1001-A has successfully completed the initial dose of 60 mg/m and is now enrolling patients in the higher dose cohort of 90 mg/m, with plans for further studies in combination with chemotherapy [6]. - In the Phase 2 study of prexigebersen for AML, two elderly patients have remained in complete remission after two years of treatment, demonstrating the drug's potential for long-term efficacy [3][8]. Group 2: Patient Outcomes - An elderly female patient with gynecologic cancer experienced a 15% reduction in her primary tumor after six cycles of BP1001-A treatment, contributing to improved quality of life and ability to engage in rigorous exercise [4]. - The first AML patient reported has received 20 cycles of treatment over 26 months and remains in complete remission, while another patient has received 16 cycles over 20 months, also maintaining complete remission [7][8]. Group 3: Company Overview - Bio-Path Holdings is focused on developing its proprietary DNAbilize technology, which has led to a pipeline of RNAi nanoparticle drugs, including prexigebersen and BP1001-A, targeting various cancers and obesity-related conditions [9].
Bio-Path Holdings Provides Key Clinical Updates